Updated interim results from U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial of Alpha DaRT for patients with recurrent GBM announced
Uzi Sofer, CEO of Alpha Tau, commented: “In May we shared the first three patients treated with Alpha DaRT in the brain. Six months later, we see how truly transformational Alpha DaRT could be for recurrent GBM. Eight patients have been treated, every procedure has gone as planned, and every one of those patients is alive. The trial thus far has exceeded our wildest expectations, particularly in such a difficult cancer. Glioblastoma is one of the most devastating diagnoses in oncology, and recurrence is virtually inevitable. We look forward to following these patients’ progress as their scans mature, and to continuing enrollment toward 20 patients, which we believe, based on initial discussions, may support market submission requirements for Alpha DaRT in patients with this disease.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib